John Brassil (Kerry, Fianna Fail) | Oireachtas source

The terms of reference should also include examining processes in place in other countries, particularly Scotland and Sweden. The review might also examine whether the 2013 Act directly blocks us from adopting the practices in those countries, from which we could learn. Does that need to be changed? Does the review include a specific mandate for improving access for patients? Did I pick that up in what Mr. Breslin said? I reiterate that there does need to be significant consultation with clinicians, patients and the industry for it to be effective. It should not be an iterative process. It should evolve and should not be a once-off review.